Warning letter
GlaxoSmithKline Biologics S.A.: warning letter of Jul 6, 2004
FDA warning letter UCM146871 · Center for Biologics Evaluation and Research
Key facts
| Reference number | UCM146871 |
|---|---|
| Company | GlaxoSmithKline Biologics S.A. |
| Subject | Promotional Claims/False & Misleading |
| Issue date | Jul 6, 2004 |
| Posted date | Jul 6, 2004 |
| Issuing office | Center for Biologics Evaluation and Research |
| Product type | Biologics |
| CFR sections cited | 202.1 |
| Country | 3 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: